A Novel Endoscopic Hemorrhoid Recurrence Score (Endo-HRS) Model for the Prediction of Internal Hemorrhoids Recurrence: A Prospective Multi-Center Clinical Trial

Feiyu Zhang[1*], Fengyu Gao[2], Wen Wang[3], Wulian Lin[3], Hao Zhang[4], Kezhou Wang[5], Qingjing Wang[1,6], Aojia Jin[1], Ruping Yang[1], Chunying Qu[1], Yi Zhang[1], Ye Hu[1], Zhenghong Li[1], Dou Wang[7], Cuicui Shi[1], Tianben Shen[1], Fei Shen[1], Leiming Xu[1],and Feng Shen[1,7†]

1. Department of Gastroenterology & Endoscopy, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
2. Department of Endoscopy, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan 250014, Shandong Province, China
3. Department of Gastroenterology, The 900th Hospital of the People's Liberation Army Joint Service Support Force, Fuzhou 350025, Fujian Province, China
4. Department of Endoscopy, Baoshan People's Hospital of Yunnan Province, Baoshan 678000, Yunnan Province, China
5. Department of Pathology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
6. Department of Gastroenterology, Jinshan Hospital of Fudan University, Shanghai 201508, China
7. Department of Gastroenterology, Shigatse People's Hospital, Shigatse, Tibet 857000, China.

Funding: The Construction Project of the "Discipline Peak-Climbing Plan" of Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine， No. XKPF2024B404

First author: Feiyu Zhang

E-mail: zhangfeiyu213@163.com

Corresponding author: Feng Shen

E-mail: shenfeng01@xinhuamed.com.cn

Clinical trial No. NCT04398823.

ABSTRACT

Background Endoscopic foam sclerotherapy is widely used for grade I internal hemorrhoids but is limited by high recurrence. No validated endoscopic tool exists to predict recurrence, and the underlying pathological mechanisms remain unclear. **Methods** A prospective multi-center cohort was enrolled. Anthropometric and endoscopic features were analyzed using a time-dependent Cox model to develop the prediction model. External cohort and multi-modal verification including endoscopic and histopathological imaging were utilized for further validation. **Results** 483 patients were enrolled, including 246 males. Cumulative recurrence rates were 0.62%, 2.48%, 10.1%, and 20.0% at 6, 12, 24, and 36 months. Number of hemorrhoids, maximum diameter, red color sign and sex were regarded as predictors of the model (Endo-HRS), which showed robust discrimination (C-index 0.82, AUC >0.80) and stratified patients into three risk groups (<18.2, 18.2~27.4, ≥27.4) for tailored follow-up. Recurrent lesions exhibited submucosal microvascular congestion and aberrant extracellular matrix deposition pathologically. **Conclusions** The Endo-HRS model enables reliable risk stratification for recurrence of foam sclerotherapy in grade I hemorrhoids, with strong external validity. It provides a practical tool for individualized preoperative assessment and treatment planning, addressing a critical gap in endoscopic hemorrhoid management.

The study is registered at ClinicalTrials.gov (www.clinicaltrials.gov). The clinical trial number is NCT04398823.

KEY WORDS

Internal hemorrhoids, Prediction model, Endoscopic predictor, Tissue pathological verification, Recurrence rate

INTRODUCTION

Internal hemorrhoids are among the most common anorectal disorders, affecting up to 40% of adults, especially individuals over 40 years, and are characterized by symptomatic enlargement or distal displacement of the hemorrhoidal cushions,

resulting in symptoms such as bleeding, prolapse, and discomfort[1, 2]. A wide spectrum of therapeutic options exists, ranging from conservative management to definitive surgical interventions[3, 4]. Among these, endoscopic foam sclerotherapy with polidocanol has gained attention as a minimally invasive approach with rapid recovery and fewer postoperative complications[5-7]. Nevertheless, recurrence remains a major limitation, with rates of 10-30% reported within the first year[8, 9], attributable to heterogeneous evaluation criteria and subjective clinical assessment. Previous studies have not systematically analyzed these factors, and the widely applied Goligher classification has inherent limitations that contribute to inconsistencies in recurrence reporting.

The aim of the multicenter prospective cohort study was to identify predictive factors and establish a novel model for endoscopic hemorrhoid recurrence, with the goal of optimizing treatment strategies.

METHODS

Study design and population

This prospective multicenter cohort study was conducted between January 2018 and December 2022 at four tertiary Gastroenterology and Endoscopy centers in China, Shanghai Xinhua Hospital, Shandong Provincial Maternal and Child Health Care Hospital, the 900th Hospital of the PLA Joint Service Support Force, Fuzhou, and Baoshan People's Hospital, Yunnan. The study aimed to develop and validate an endoscopic model for predicting hemorrhoid recurrence after foam sclerotherapy.

Eligible participants were adults (18-60 yrs) diagnosed with Goligher grade I hemorrhoids confirmed by endoscopic examination and treated with 1% (20mg/2mL) polidocanol foam. Patients with advanced hemorrhoids, coexisting anorectal disorders, or contraindications to sclerotherapy were excluded. Consecutive patients were prospectively enrolled. The detailed inclusion and exclusion criteria are presented in Supplementary Table S1 & S2.

The study protocol was approved by the Ethics Committee of Xinhua Hospital (XHEC-C-2020-003-1). The study is registered at ClinicalTrials.gov

(www.clinicaltrials.gov). The clinical trial number is NCT04398823. Written informed consent was obtained from all participants in accordance with the Declaration of Helsinki.

Foam sclerotherapy was carried out using the standardized techniques in our previous literature. Specifically, foam sclerotherapy was prepared by the tessari method

Endoscopic procedure and data collection

Patients followed a low-fiber diet the day before colonoscopy and underwent split-dose bowel preparation using polyethylene glycol solution, according to ESGE guidelines[10]. Foam sclerotherapy was carried out using the technique in previous literature[11]. Specifically, 1% polidocanol (Hameln Pharmaceuticals, Germany) was prepared by Tessari's method[12] and injected through a 23-gauge Interject™ needle (Boston Scientific, United States) under endoscopic visualization (Olympus H290 series, Japan).

Two experienced endoscopists recorded predefined variables, including the number of hemorrhoids, maximum diameter, degree of red color sign, mucosal erosion, and degree of dentate line damage. The red color sign was classified from 0 to 3 based on vascular congestion severity (Supplementary Figure S1). Mucosal erosion was classified as 0 or 1 based on its presence or absence. The degree of dentate line damage was classified from 0 to 2 according to the extent of injury observed under endoscopy (0: no damage; 1: damage < 0.5 cm; 2: damage ≥ 0.5 cm).

Follow-up and outcomes

All patients were followed for at least 6 months with clinic visits every 3 months, including inquires, digital rectal examination, questionnaire assessment (Supplementary Table S3), and colonoscopy every 6 months. Follow-up was extended up to 36 months in patients without recurrence and terminated immediately upon relapse. Recurrence was defined as reappearance of bleeding symptoms reported by the patient, upon which a colonoscopy re-examination should be performed to assess the severity of hemorrhoids. Recurrence time was recorded as months.

Model development and validation

Candidate predictors were selected from baseline clinical and endoscopic

variables. Univariable Cox proportional hazards analyses identified variables with $P < 0.10$ for entry into multivariable modeling. The final model was determined by backward stepwise selection. The proportional hazards assumption was verified using Schoenfeld residuals, and hazard ratios (HRs) with 95% confidence intervals (CIs) were reported.

The **Endo**scopic **H**emorrhoid **R**ecurrence **S**core **(Endo-HRS)** was constructed by assigning weighted points to independent predictors according to their regression coefficients. The model's discrimination and calibration were assessed using Harrell's concordance index (C-index), time-dependent receiver operating characteristic (tROC) curves, and calibration plots. Internal validation was performed using 1000 bootstrap resamples.

Patients were stratified into A, B, and C groups based on the Youden-optimized cutoff, and recurrence-free survival among groups was compared by Kaplan-Meier analysis. External validation was performed in an independent cohort with the same definitions and analytic strategy.

Multi-modal verification

To enhance the effectiveness and clinical applicability, multi-modal verification cohort including histopathological and endoscopic images were obtained. A subset of 40 participants (9 of group A, 24 of group B, and 7 of group C) underwent multimodal verification. Two blinded endoscopists independently reviewed endoscopic images to assess recurrence. Disagreements were resolved by consensus with a third reviewer.

Biopsy samples were processed for hematoxylin-eosin (H&E) and Masson's trichrome staining to evaluate vascular congestion and collagen deposition. Microvascular analysis and collagen proportionate area were quantified using ImageJ software[13].

Statistical analysis

Continuous variables were summarized as means ± standard deviation (SD) or medians (interquartile range, IQR), and categorical variables as frequencies (%). Group comparisons were performed using the χ^2 or Wilcoxon rank-sum test, as appropriate. Model discrimination and calibration were evaluated as described above. Missing

values were handled using multiple imputation by chained equations.

All analyses were performed using R (version 4.5.1, R Core Team (2025). _R: A Language and Environment for Statistical Computing_. R Foundation for Statistical Computing, Vienna, Austria. <https://www.R-project.org/>) and SPSS (IBM SPSS Statistics for Windows, version 27.0, IBMCorp., Armonk, N.Y., USA). Relevant packages were listed in Supplementary Table S4. Custom R scripts for data processing and figure generation are available from the corresponding author upon reasonable request.

Statistical significance was set at $P < 0.05$. The study followed the TRIPOD reporting guideline for prognostic model development.

RESULTS

Patient characteristics and follow-up

A total of 504 patients with grade I hemorrhoids were enrolled. 12 patients were excluded owing to age >60 yrs, use of anticoagulant or antiplatelet therapy, or intolerance to endoscopic treatment. 9 patients were lost to follow-up. Ultimately, 483 patients completed follow-up and were included in the analysis subsequently. 50.9% (246/483) of patients were male, and the median age was 52.5 years (IQR 44-62). 23.8% (115/483) of patients experienced recurrence. Median age did not differ significantly between recurrence and non-recurrence groups (55.0 ± 21.0 vs 55.0 ± 18.0 years, P=0.819). The recurrence group had a higher proportion of men (61.7%, 71/115) than the non-recurrence group (47.6%, 175/368, P=0.008). Patients with recurrence had a shorter follow-up duration (27.4 ± 9.3 vs 61.0 ± 11.0 months, P<0.001) (Table 1A).

Recurrence occurred in 0.6% (3/483), 2.5% (12/483) and 10.1% (49/483) of patients (3/483) at 6, 12 and 24 months, respectively. At 36 months, recurrence rate rose to 20.0% (97/483). These findings suggest that foam sclerotherapy provides durable efficacy and safety for grade I hemorrhoids.

Endoscopic characteristics

The recurrence group had a greater number of hemorrhoids (P<0.001). Three or more hemorrhoids were observed in 86.1% (99/115) of recurrent cases, compared with

52.7% (194/368) in non-recurrent cases. The maximum diameter was larger in recurrence group (P<0.001). Red color signs with linear or large-area distribution were more frequent in recurrence group (38.3% vs 17.1%, P<0.001). No significant differences were observed in mucosal erosion (P=0.254) or dentate line damage (P=0.264) (Table 1B).

Endo-HRS model construction

Based on these endoscopic characteristics, we developed the new prediction model. The number of hemorrhoids (P<0.0001), maximum diameter (P<0.0001), and red color signs (P<0.0001) were identified as strongly independent predictors. Although there was no statistical difference in terms of male sex (P=0.0083), it was also retained in the model due to clinical relevance (Figure 1). All four variables conformed to the proportional hazard assumption.

The final model (Formula 1) demonstrated excellent discrimination with multicollinearity (Supplementary Table S5). Time-dependent ROC analysis confirmed model stability (Supplementary Figure S2). Predicted probabilities closely matched observed recurrence in internal validation (Supplementary Figure S3).

$$Risk\ scores = 1 \times Sex(male) + 4 \times Num + 11 \times Dia + 2 \times RCS$$

Formula 1 The mathematical formula of the Endo-HRS model. **Abbreviations: Sex:** Male is represented as 1, and female as 0; **Num:** the number of hemorrhoids; **Dia:** the maximum diameter of hemorrhoids, **RCS:** the degree of red color sign.

According to the model, patients were stratified into quartile-based risk groups (low, moderate, high, very high) (Supplementary Table S6). For clinical applicability, a simplified three-tier system (Endo-HRS A, B, C) was proposed (Supplementary Table S7), which showed good discrimination at 36 months (AUC=0.864, Youden cutoff=22.8, Figure 2A). Recurrence-free probability decreased progressively across risk groups (Figure 2B). Individual risk of recurrence could also be estimated under nomogram (Figure 2C).

External and multi-modal verification

To evaluate the prediction model more comprehensively, external cohort and multi-modal validation were performed (Supplementary Table S8). Endo-HRS

demonstrated strong discrimination (Bootstrap-corrected C-index=0.900, 95%CI [0.862-0.933]) in the external cohort, with time-dependent AUCs >0.90 at 24, 36, and 48 months (Figure 3A). Calibration curves showed good agreement between predicted and observed recurrence (Supplementary Figure S4). Patients in group C had significantly shorter recurrence-free probability than those in group A and B (P<0.0001, Figure 3B).

In the endoscopic imaging cohort, recurrence risk increased across groups. Higher-risk patients showed more prominent red color signs, greater number, and larger diameters (Figure 4A-C). These findings indicated that Endo-HRS scores and risk classification corresponded to the endoscopic manifestations of hemorrhoids and were associated with the outcomes (P<0.001).

Furthermore, histopathological analysis was applied for validation. Patients in Endo-HRS C group showed marked dilation and congestion of small veins (Figure 4D-F), consistent with more severe bleeding clinically. Masson's staining revealed denser collagen in higher-risk groups (Figure 4G-I), with 14.6-fold and 2.6-fold higher in group C than A and B, respectively (Supplementary Table S9, Figure S5). These resulted demonstrated the consistency between pathological findings and clinical model. It also revealed that the recurrence risk of hemorrhoids might be related to vascular and collagen factors.

DISCUSSION

In this study, we conducted the first clinical investigation to evaluate 3-year recurrence rate of 1% polidocanol foam sclerotherapy for grade I internal hemorrhoids. To date, no study has focused exclusively on this subgroup with long-term outcomes. Importantly, we proposed the Endo-HRS model, the first recurrence prediction model derived from endoscopic features. Unlike prior symptom-based classifications, Endo-HRS incorporates objective endoscopic parameters and, for the first time, underwent multi-modal validation through external clinical cohorts, endoscopic imaging, and histopathological analysis. This approach not only confirmed the robustness of the model, but established a novel framework that links clinical manifestations with

underlying mechanisms.

Recurrence increased progressively with follow-up, reaching 2.5% at 1 year, 10.1% at 2 years, and 20.0% at 3 years. These findings are consistent with previous reports[6, 14], although prior studies predominantly employed 3% (60mg/2mL) polidocanol and included patients with grade II-III hemorrhoids[6, 14-16]. Our results suggest that 1% polidocanol foam in grade I disease reduces local irritation while maintaining efficacy, with lower recurrence rates compared with earlier studies[11] 错误!未找到引用源。. Importantly, no severe complications such as thrombosed hemorrhoids or perianal abscesses occurred, underscoring the safety of this approach. Compared with the 12-28% recurrence reported with 3% polidocanol in grade II hemorrhoids[17], our 20% recurrence at 3 years in grade I disease demonstrates favorable outcomes.

As a "billion-dollar industry"[18], the attention to internal hemorrhoids is actually very limited. Traditional systems such as Goligher's classification emphasize prolapse but fail to account for bleeding and other symptoms[19], while newer classifications, such as BPRST[20], remain largely symptom-based. Prior research has explored subjective factors such as constipation, pruritus, and lifestyle habits[21-23]. In contrast, our model incorporated objective endoscopic indicators, including hemorrhoid number (HR of 3.39), diameter (HR of 22.94), and red color sign (HR of 1.67), which were strong independent predictors of recurrence. Although male sex did not retain statistical significance, it was included based on prior literature[21] and clinical relevance (61.7% recurrence vs 47.6% no-recurrence), without compromising model validity.

In the modeling process, we classified patients into four categories according to the quartiles of the risk scores, thereby stratifying them into distinct risk levels. Kaplan-Meier analysis demonstrated significant differences in recurrence risk across these categories, confirming the discriminative ability of the model (Supplementary Figure S6). Nevertheless, this stratification approach may be cumbersome in clinical practice, as repeated endoscopic assessments are difficult to justify and may ultimately reduce patient compliance.

To enhance clinical applicability, we simplified risk stratification into Endo-HRS A-C groups. This practical system balances disease management with medical resource

allocation. For example, patients with scores <18.2 may safely defer repeat colonoscopy for 2-3 years, while those with scores ≥27.4 should undergo regular surveillance and early retreatment. Such stratification provides actionable guidance for individualized follow-up strategies.

The multi-modal verification strategy was adopted to strengthen the robustness and interpretability of the Endo-HRS model. By integrating endoscopic imaging and histopathology, we confirmed the reliability of recurrence risk stratification, gaining mechanistic insights ulteriorly. While hemorrhoids impose a substantial clinical burden[21], most studies have focused on symptoms, with limited exploration of biological mechanisms. Recent genomic evidence has provided new perspectives. Zheng et al.[24] demonstrated the heritability of hemorrhoids, linking them to vascular pathways and extracellular matrix (ECM) remodeling, while Sninsky et al.[25] suggested shared genetic determinants with diverticulosis through connective tissue alterations.

Our findings complement these data. Higher-risk patients showed larger hemorrhoids and more prominent red color signs on endoscopy, consistent with vascular hyperplasia. Histologically, H&E staining revealed congested vessels, and Masson's staining demonstrated increased collagen deposition, correlating with recurrence. Given that collagen is a key ECM component[26] and that ECM integrity underpins vascular homeostasis[27], these results support a mechanism whereby abnormal ECM remodeling and collagen overproduction drive recurrence. Taken together, these multi-modal findings provide a pathophysiological basis linking clinical features with biological mechanisms, reinforcing the validity and translational potential of the Endo-HRS model.

This study has limitations. First, further external validation in larger cohorts and across different hemorrhoid grades is warranted. Second, although endoscopic features are more objective than symptoms, inter-observer variability remains a concern. Structured training and standardized rubrics may improve reproducibility, and artificial intelligence applications could further enhance reliability. Third, mechanistic insights derived from histological observations require additional in vivo validation.

In conclusion, this study establishes an endoscopy-based model for predicting

recurrence after foam sclerotherapy for internal hemorrhoids. The Endo-HRS offers practical stratification for follow-up and treatment planning, contributing to the development of personalized care in hemorrhoidal disease.

Competing interests

The authors declare that they have no conflict of interest.

REFERENCE

1. Tomasicchio G, Martines G, Lantone G et al. Safety and Effectiveness of Tailored Hemorrhoidectomy in Outpatients Setting. Front Surg 2021; 8: 708051. doi:10.3389/fsurg.2021.708051
2. Lee KC, Liu CC, Hu WH et al. Risk of delayed bleeding after hemorrhoidectomy. Int J Colorectal Dis 2019; 34: 247-253. doi:10.1007/s00384-018-3176-6
3. Sikakulya FK, Ssebuufu R, Okedi XF et al. Pain assessment following open hemorrhoidectomy under local anesthesia versus saddle block: a multicenter randomized controlled trial. BMC Surg 2023; 23: 124. doi:10.1186/s12893-023-02030-6
4. Lauricella S, Palmisano D, Brucchi F et al. Long-term results and quality of life after stapled hemorrhoidopexy vs Doppler-guided HAL-RAR: a propensity score matching analysis. Int J Colorectal Dis 2024; 39: 30. doi:10.1007/s00384-024-04603-0
5. Zhang FM, Wu KC, Li JN et al. Rationale, new anus positioning methods, and updated protocols: Expert recommendations on cap-assisted endoscopic sclerotherapy for hemorrhoids from China Gut Conference. Chin Med J (Engl) 2021; 134: 2675-2677. doi:10.1097/cm9.0000000000001836
6. Salgueiro P, Garrido M, Santos RG et al. Polidocanol Foam Sclerotherapy Versus Rubber Band Ligation in Hemorrhoidal Disease Grades I/II/III: Randomized Trial. Dis Colon Rectum 2022; 65: e718-e727. doi:10.1097/dcr.0000000000002117
7. Gallo G, Grossi U, De Simone V et al. Real-world use of polidocanol foam sclerotherapy for hemorrhoidal disease: insights from an international survey and systematic review with clinical practice recommendations. Updates Surg 2025; 77: 1439-1450. doi:10.1007/s13304-025-02258-2
8. Wu X, Wen Q, Cui B et al. Cap-assisted endoscopic sclerotherapy for internal hemorrhoids: technique protocol and study design for a multi-center randomized controlled trial. Ther Adv Gastrointest Endosc 2020; 13: 2631774520925636. doi:10.1177/2631774520925636
9. Takada S, Tsunoda A, Takahashi T et al. Early postoperative outcomes of a novel nonexcisional technique using aluminum potassium sulfate and tannic acid sclerotherapy with mucopexy on patients with grade III hemorrhoids. Ann Coloproctol 2022; 38: 290-296. doi:10.3393/ac.2020.00920.0131
10. Hassan C, East J, Radaelli F et al. Bowel preparation for colonoscopy: European

Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2019. Endoscopy 2019; 51: 775-794. doi:10.1055/a-0959-0505

11. Qu CY, Zhang FY, Wang W et al. Endoscopic polidocanol foam sclerobanding for the treatment of grade II-III internal hemorrhoids: A prospective, multi-center, randomized study. World J Gastroenterol 2024; 30: 3326-3335. doi:10.3748/wjg.v30.i27.3326
12. Tessari L, Cavezzi A, Frullini A. Preliminary experience with a new sclerosing foam in the treatment of varicose veins. Dermatol Surg 2001; 27: 58-60
13. Schroeder AB, Dobson ETA, Rueden CT et al. The ImageJ ecosystem: Open-source software for image visualization, processing, and analysis. Protein Sci 2021; 30: 234-249. doi:10.1002/pro.3993
14. Gallo G, Pietroletti R, Novelli E et al. A multicentre, open-label, single-arm phase II trial of the efficacy and safety of sclerotherapy using 3% polidocanol foam to treat second-degree haemorrhoids (SCLEROFOAM). Tech Coloproctol 2022; 26: 627-636. doi:10.1007/s10151-022-02609-w
15. Lobascio P, Laforgia R, Novelli E et al. Short-Term Results of Sclerotherapy with 3% Polidocanol Foam for Symptomatic Second- and Third-Degree Hemorrhoidal Disease. J Invest Surg 2021; 34: 1059-1065. doi:10.1080/08941939.2020.1745964
16. Neves S, Falcão D, Povo A et al. 3% polidocanol foam sclerotherapy versus hemorrhoidal artery ligation with recto anal repair in hemorrhoidal disease grades II-III: a randomized, pilot trial. Rev Esp Enferm Dig 2023; 115: 115-120. doi:10.17235/reed.2022.8568/2022
17. Gallo G, Picciariello A, Pietroletti R et al. Sclerotherapy with 3% polidocanol foam to treat second-degree haemorrhoidal disease: Three-year follow-up of a multicentre, single arm, IDEAL phase 2b trial. Colorectal Dis 2023; 25: 386-395. doi:10.1111/codi.16380
18. Cosman BC. Piles of Money: "Hemorrhoids" Are a Billion-Dollar Industry. Am J Gastroenterol 2019; 114: 716-717. doi:10.14309/ajg.0000000000000234
19. Dekker L, Han-Geurts IJM, Grossi U et al. Is the Goligher classification a valid tool in clinical practice and research for hemorrhoidal disease? Tech Coloproctol 2022; 26: 387-392. doi:10.1007/s10151-022-02591-3
20. Margetis N. Pathophysiology of internal hemorrhoids. Ann Gastroenterol 2019; 32: 264-272. doi:10.20524/aog.2019.0355
21. Sandler RS, Peery AF. Rethinking What We Know About Hemorrhoids. Clin Gastroenterol Hepatol 2019; 17: 8-15. doi:10.1016/j.cgh.2018.03.020
22. Lohsiriwat V, Sheikh P, Bandolon R et al. Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review. Adv Ther 2023; 40: 117-132. doi:10.1007/s12325-022-02351-7
23. Rørvik HD, Styr K, Ilum L et al. Hemorrhoidal Disease Symptom Score and Short Health ScaleHD: New Tools to Evaluate Symptoms and Health-Related Quality of Life in Hemorrhoidal Disease. Dis Colon Rectum 2019; 62: 333-342. doi:10.1097/dcr.0000000000001234
24. Zheng T, Ellinghaus D, Juzenas S et al. Genome-wide analysis of 944 133 individuals provides insights into the etiology of haemorrhoidal disease. Gut 2021; 70: 1538-1549. doi:10.1136/gutjnl-2020-323868

25. Sninsky JA, Galanko J, Sandler RS et al. Diverticulosis Is Associated With Internal Hemorrhoids on Colonoscopy: Possible Clues to Etiology. Clin Gastroenterol Hepatol 2023; 21: 1097-1099.e1093. doi:10.1016/j.cgh.2022.02.020
26. De Martino D, Bravo-Cordero JJ. Collagens in Cancer: Structural Regulators and Guardians of Cancer Progression. Cancer Res 2023; 83: 1386-1392. doi:10.1158/0008-5472.Can-22-2034
27. Fu Y, Zhou Y, Wang K et al. Extracellular Matrix Interactome in Modulating Vascular Homeostasis and Remodeling. Circ Res 2024; 134: 931-949. doi:10.1161/circresaha.123.324055

FIGURE LEGENDS



Graphical Abstract Schematic of the prospective multicenter clinical study, the construction of Endo-HRS model, and multi-modal verification of the model.



Fig 1. Forest plot of predictors identified by the Endo-HRS model.



Figure 2. Discriminative capacity and visualization of the Endo-HRS model. A. Time-dependent ROC curve of recurrence prediction at 36 months. The red, green, and blue dots represent rule-in, Youden, and Rule-out score, respectively. B. Kaplan-Meier survival curves for Endo-HRS A (blue curve), B (green curve), and C (red curve) groups of Endo-HRS model. C. Nomogram for predicting 36-month recurrence probability. **Abbreviations:** ROC: Receiver Operating Characteristic; AUC: Area Under Curve; mo: months.



Figure 3. Discriminative capacity of the Endo-HRS model in the external cohort. A. Time-dependent ROC curve of recurrence prediction at 24 (the red curve), 36 (the green curve), and 48

(the blue curve) months. respectively. B. Kaplan-Meier survival curves for A (the blue curve), B (the green curve), and C (the red curve) groups of Endo-HRS model.



Figure 4. Multi-modal verification of Endo-HRS model. A-C. Endoscopic images of Endo-HRS A, B, and C groups, respectively (Black arrows: hemorrhoids; White arrows: red color signs). D-F. H&E staining of Endo-HRS A, B, and C groups, respectively (scale bar = 50 μm) (Black triangles: enlarged blood vessels). G-I. Masson staining of Endo-HRS A, B, and C groups, respectively (scale bar = 50 μm).

Table 1. Baseline clinical (A) and endoscopic (B) characteristics of patients in recurrence and no recurrence groups.

A.

Participants (n=483)		Recurrence (n=115)	No recurrence (n=368)	P value
Age		55.0±21.0	55.0±18.0	0.819
Sex	**Male**	61.7% (n=71)	47.6% (n=175)	0.008**
	Female	38.3% (n=44)	52.4% (n=193)	
Follow-up period		27.4±9.3	61.0±11.0	<0.001***

B.

Participants (n=483)	Number of hemorrhoids					Maximum diameter of hemorrhoids		
	1	**2**	**3**	**4**	**5**	**<0.8cm**	**0.8cm≤Dia.<1.2cm**	**≥1.2cm**
Recurrence (n=115)	0.0% (n=0)	13.9% (n=16)	62.6% (n=72)	22.6% (n=26)	0.9% (n=1)	3.5% (n=4)	61.7% (n=71)	34.8% (n=40)
No recurrence (n=368)	8.4% (n=31)	38.9% (n=143)	49.7% (n=183)	3.0% (n=11)	0.0% (n=0)	34.2% (n=126)	54.9% (n=202)	10.9% (n=40)
P value	<0.001***					<0.001***		

(Continued)

Participants (n=483)	Score of red color signs				Mucosa erosion		Dentate line damage		
	0	**1**	**2**	**3**	**No**	**Yes**	**0**	**<0.5cm**	**≥0.5cm**
Recurrence (n=115)	4.3% (n=5)	57.4% (n=66)	27.0% (n=31)	11.3% (n=13)	91.3% (n=105)	8.7% (n=10)	87.8% (n=101)	9.6% (n=11)	2.6% (n=3)
No recurrence (n=368)	41.6% (n=153)	41.3% (n=152)	17.1% (n=63)	0.0% (n=0)	94.3% (n=347)	5.7% (n=21)	91.3% (n=336)	7.1% (n=26)	1.6% (n=6)
P value	<0.001***				0.254		0.264		

P value: * <0.05, ** <0.01, *** <0.001

A Novel Endoscopic Hemorrhoid Recurrence Score (Endo-HRS) Model for the Prediction of Internal Hemorrhoids Recurrence: A Prospective Multi-Center Clinical Trial

Feiyu Zhang[1*], Fengyu Gao[2], Wen Wang[3], Wulian Lin[3], Hao Zhang[4], Kezhou Wang[5], Qingjing Wang[1,6], Aojia Jin[1], Ruping Yang[1], Chunying Qu[1], Yi Zhang[1], Ye Hu[1], Zhenghong Li[1], Dou Wang[7], Cuicui Shi[1], Tianben Shen[1], Fei Shen[1], Leiming Xu[1],and Feng Shen[1,7†]

1. Department of Gastroenterology & Endoscopy, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China.
2. Department of Endoscopy, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan 250014, Shandong Province, China
3. Department of Gastroenterology, The 900th Hospital of the People's Liberation Army Joint Service Support Force, Fuzhou 350025, Fujian Province, China
4. Department of Endoscopy, Baoshan People's Hospital of Yunnan Province, Baoshan 678000, Yunnan Province, China
5. Department of Pathology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
6. Department of Gastroenterology, Jinshan Hospital of Fudan University, Shanghai 201508, China
7. Department of Gastroenterology, Shigatse People's Hospital, Shigatse, Tibet 857000, China.

FIGURE LEGENDS



Graphical Abstract Schematic of the prospective multicenter clinical study, the construction of Endo-HRS model, and multi-modal verification of the model.



Fig 1. Forest plot of predictors identified by the Endo-HRS model.



Figure 2. Discriminative capacity and visualization of the Endo-HRS model. A. Time-dependent ROC curve of recurrence prediction at 36 months. The red, green, and blue dots represent rule-in, Youden, and Rule-out score, respectively. B. Kaplan-Meier survival curves for Endo-HRS A (blue curve), B (green curve), and C (red curve) groups of Endo-HRS model. C. Nomogram for predicting 36-month recurrence probability. **Abbreviations:** ROC: Receiver Operating Characteristic; AUC: Area Under Curve; mo: months.



Figure 3. Discriminative capacity of the Endo-HRS model in the external cohort. A. Time-dependent ROC curve of recurrence prediction at 24 (the red curve), 36 (the green curve), and 48 (the blue curve) months. respectively. B. Kaplan-Meier survival curves for A (the blue curve), B (the green curve), and C (the red curve) groups of Endo-HRS model.



Figure 4. Multi-modal verification of Endo-HRS model. A-C. Endoscopic images of Endo-HRS A, B, and C groups, respectively (Black arrows: hemorrhoids; White arrows: red color signs). D-F. H&E staining of Endo-HRS A, B, and C groups, respectively (scale bar = 50 μm) (Black triangles: enlarged blood vessels). G-I. Masson staining of Endo-HRS A, B, and C groups, respectively (scale bar = 50 μm).